Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
Ardelyx (NASDAQ: ARDX), a biopharmaceutical company focused on developing first-in-class medicines for unmet medical needs, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. President and CEO Mike Raab will engage in a fireside chat on June 4, 2025, at 8:10 am ET in New York. The presentation will be accessible via live webcast on the company's website, with a replay available for 30 days following the event.
Ardelyx (NASDAQ: ARDX), un'azienda biofarmaceutica specializzata nello sviluppo di farmaci innovativi per bisogni medici insoddisfatti, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference 2025. Il Presidente e CEO Mike Raab parteciperà a una chiacchierata informale il 4 giugno 2025 alle 8:10 ET a New York. La presentazione sarà disponibile in diretta streaming sul sito web dell'azienda, con una replica accessibile per 30 giorni dopo l'evento.
Ardelyx (NASDAQ: ARDX), una compañía biofarmacéutica enfocada en desarrollar medicamentos innovadores para necesidades médicas no cubiertas, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference 2025. El presidente y CEO Mike Raab participará en una charla informal el 4 de junio de 2025 a las 8:10 am ET en Nueva York. La presentación estará disponible en transmisión en vivo en el sitio web de la compañía, con una repetición accesible durante 30 días después del evento.
Ardelyx (NASDAQ: ARDX)는 충족되지 않은 의료 수요를 위한 혁신적인 신약 개발에 주력하는 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference 2025에 참여할 예정임을 발표했습니다. 사장 겸 CEO Mike Raab는 2025년 6월 4일 오전 8시 10분 ET에 뉴욕에서 진행되는 비공식 대화에 참석합니다. 발표는 회사 웹사이트를 통해 생중계되며, 행사 후 30일 동안 다시보기로 제공됩니다.
Ardelyx (NASDAQ : ARDX), une société biopharmaceutique spécialisée dans le développement de médicaments innovants pour des besoins médicaux non satisfaits, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference 2025. Le président-directeur général Mike Raab participera à une discussion informelle le 4 juin 2025 à 8h10 ET à New York. La présentation sera accessible en direct sur le site web de l'entreprise, avec une rediffusion disponible pendant 30 jours après l'événement.
Ardelyx (NASDAQ: ARDX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Medikamente für ungedeckte medizinische Bedürfnisse spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference 2025 bekannt gegeben. Präsident und CEO Mike Raab wird am 4. Juni 2025 um 8:10 Uhr ET in New York an einem informellen Gespräch teilnehmen. Die Präsentation wird live über die Website des Unternehmens übertragen, mit einer Wiedergabe, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025 at 8:10 am ET in New York.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When is Ardelyx (ARDX) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Ardelyx (ARDX) at the Jefferies Healthcare Conference 2025?
How can investors access Ardelyx's (ARDX) presentation at the Jefferies Conference?
What is Ardelyx's (ARDX) main business focus?
